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Gene expression fingerprints in human tubulointerstitial in-
flammation and fibrosis as prognostic markers of disease pro-
gression.
Background. Gene expression profiling of nephropathies
may facilitate development of diagnostic strategies for com-
plex renal diseases as well as provide insight into the molecular
pathogenesis of kidney diseases. To test molecular based re-
nal disease categorization, differential gene expression profiles
were compared between control and hydronephrotic kidneys
showing varying degrees of inflammation and fibrosis.
Methods. RNA expression profiles from 9 hydronephrotic
and 3 control kidneys were analyzed using small macroarrays
dedicated to genes involved in cell-cell contact, matrix turnover,
and inflammation. In parallel, the degree of tubulointerstitial in-
flammation, fibrosis, and tubular atrophy using light microscopy
and quantitative immunohistochemical parameters was deter-
mined.
Results. Hierarchic clustering and self-organizing maps led to
a gene expression dendrogram with three distinct nodes repre-
senting the control group, four kidneys with high inflammation,
and five kidneys giving high fibrosis scores. To evaluate the clin-
ical applicability of the marker set, the expression of nine genes
(6Ckine, IL-8, MMP-9, MMP-3, MMP-7, urokinase R, CXCR5,
integrin-b4, and pleiotrophin) was tested in tubulointerstitial
samples from routine renal biopsies. Seven mRNA markers
showed differential regulation in inflammation and fibrosis in
the biopsy population. Clinical follow-up revealed stringent cor-
relation between gene expression data and progression of renal
disease, and allowed segregation of the biopsies into progressive
or stable disease course based on gene expression profiles.
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Conclusion. This study suggests the feasibility of
gene expression–based disease categorization in human
nephropathies based on the extraction of marker gene sets.
The integration of traditional pathologic classification
of renal disease with molecular profiling is opening new
dimensions in disease management. It has been proposed
that the identification and analysis of specific gene expres-
sion patterns in renal dysfunction may facilitate molecu-
lar diagnosis, as well as provide insight into pathogenesis,
prognosis, and differential therapy [1].
To evaluate this hypothesis a paradigmatic renal dis-
ease with a clearly defined clinical end point and his-
tologic picture, as well as sufficient tissue for analysis,
is required. Hydronephrosis is a tubulointerstitial pro-
gressive renal disease caused by functional or mechanical
urinary tract obstruction. If left untreated, it leads to an
irreversible stage of scarring (tubular atrophy and inter-
stitial fibrosis) and loss of renal function [2]. For the study
described here a series of human kidneys showing differ-
ing degrees of tubulointerstitial inflammation and fibrosis
secondary to hydronephrosis were selected.
The role of specific inflammatory infiltrates in progres-
sive renal diseases in humans [3] and in experimental uri-
nary tract obstruction has received considerable attention
in the past few years [4, 5]. The extent and severity
of mononuclear infiltrates appear to correlate with the
severity of tubular atrophy and interstitial fibrosis, and
correlate with loss of renal function [3–7]. Insight into
regulatory programs activated during renal inflamma-
tion and scarring should aid in understanding underlying
disease processes, and may yield novel diagnostic infor-
mation concerning disease type, prognosis, and response
to therapy. The power of gene expression profiling in
this regard and its impact on disease classification have
been demonstrated in studies of neoplastic tissue. Gene
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expression profiles have allowed functionally based dis-
ease classifications and have predicted clinical course and
response to chemotherapy [1, 8, 9]. To this end, tumor
samples are ideally suited for this approach because they
primarily represent clonally expanded tissue with differ-
ent gene expression respective to control tissue.
Gene expression profile-based disease classification
from native human kidneys infiltrated by diverse
inflammatory cells, are now undergoing evaluation.
Chemokines, cytokines, their receptors, cell adhesion,
and matrix turnover–associated molecules, have been
identified as key players in inflammation and fibrosis [10].
A custom DNA array targeting these groups of genes was
used to assess differential mRNA expression in the pro-
gressive human disease associated with hydronephrosis.
Expression profiles allowed the identification of a com-
prehensive set of differentially expressed cDNAs. The re-
sulting marker set also showed differential regulation in
routine renal biopsy specimens according to their inflam-
matory or fibrotic activity. Correlation of clinical follow-
up data showed that the expression of a group of these
genes showed a statistical association with progression of
renal disease and allowed the segregation into progres-
sion to terminal renal failure and stable disease courses.
The clinical application of gene expression profiles should
facilitate a more accurate and objective diagnosis and
prognosis of renal diseases, and potentially, response to
treatment.
METHODS
Tissue samples and RNA preparation
Total RNA was extracted from nine hydronephrotic
(HN, N = 9, age 40.5 ± 26.6, F:M 4:5) and three control
(Con, N = 3, age 44.3 ± 4.2, F:M 2:1) kidneys using the
phenol/chloroform extraction method by Chomczynski
and Sacchi [11]. The HN kidneys were nonfunctioning
and surgically removed as a consequence of end-stage
disease.
As control, histologically verified unaffected regions
from tumor nephrectomies were used. The tissues were
shock frozen in liquid nitrogen immediately after removal
and stored at −80◦C. The RNA quality was monitored by
agarose gel electrophoresis.
Probe generation for array hybridization
To synthesize cDNA probes 2 lg of total RNA was
reverse transcribed for 2 hours at 42◦C with 4 lL
Human Cytokine cDNA Labeling Primers, 50 U
AMV Reverse Transcriptase (both from Sigma-Genosis,
Cambridge, UK), 333 mmol/L dATP, dGTP, dTTP, 20 lCi
33P-labeled dCTP (Amersham Biosciences, Piscataway,
NJ, USA), and 20 U RNase inhibitor (Amersham Bio-
sciences, Piscataway, NJ, USA).
The radioactively labeled cDNA probes were puri-
fied with S300 Mobi Spin Columns (MoBiTec GmbH,
Go¨ttingen, Germany) and hybridized for 18 hours at 65◦C
to PanoramaTM Human Cytokine Gene Arrays (Sigma
Genosys, Inc., Woodlands, TX, USA), filter arrays spot-
ted with amplified PCR products of known genes, fol-
lowing the protocol of the manufacturer. The cDNA
macroarrays contained 375 known genes representing
molecules involved in cell-cell contact (integrins), matrix
turnover (proteases and their inhibitors) and cytokines,
chemokines, and their receptors. The complete list of
genes and corresponding accession numbers can be found
at http://www.sigmagenosys.com.
The membranes were washed twice with 0.5× stan-
dard saline phosphate/EDTA (SSPE), 1% sodium
dodecyl sulfate (SDS) for 30 minutes at 65◦C, and after-
wards once with 0.1× SSPE, 1% SDS under conditions
described above. The arrays were exposed to phosphor
image screens and the signals detected with 50-lm reso-
lution on a phosphorimager (Typhoon 9210, Amersham
Biosciences). mRNA sample Con 3 was hybridized to 2
filters. This internal control sample showed significant re-
producibility, R2 = 0.9884.
Data analysis
Expression data were processed using ArrayVision
software (Imaging Research, Inc., Ontario, Canada). Lo-
cal background values were determined as on average of
intra-array blank/control spots and were subtracted from
intensity data for each gene. Duplicate spots for each gene
were averaged. To correct for differences in probe spe-
cific activities, hybridization, and other interexperimental
variables, data were normalized by dividing the intensity
of each gene to the mean intensity of all genes of the ar-
ray. Gene expression levels and samples were grouped by
hierarchic clustering. A self-organizing map and average
linkage hierarchic clustering, including an automatically
weighted voting was used to analyze the data by apply-
ing CLUSTER and TREEVIEW, developed by Eisen
MB [12] (Eisen MB, http://rana.lbl.gov/).
Morphometry and histochemistry
All samples used in the molecular analysis were eval-
uated for histologic injury: (1) interstitial inflammation;
and (2) chronic tubulointerstitial changes with tubular at-
rophy and interstitial fibrosis. To evaluate the interstitial
matrix increase, morphometric analysis was performed
using a semiautomatic image analyzing system (Leica
Q600 Qwin, Cambridge, England) in Masson Trichrome–
stained kidney sections. Interstitial matrix increase was
measured in 20 high-power fields (HPF) of cortex and
medulla tracing manually the area of interest. Results
were expressed as a percentage of the total tubulointer-
stitial area, obtained after exclusion of glomeruli.
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Immunohistochemistry (see below) was used for eval-
uation of inflammation. Neutrophil infiltration was evalu-
ated using naphtol AS-D chloroacetate esterase staining
and eosinophil infiltration by Giemsa staining by count-
ing the number of neutrophils respectively eosinophils in
20 HPF per section. Data are expressed as mean per HPF.
Immunohistochemistry (IHC)
Three Con (Con1, Con2, Con 3), three inflammatory
HN (HN1, HN2, HN7), and three fibrotic HN (HN3,
HN4, HN5) were available for detailed IHC analysis.
Immunohistochemical staining was performed on 3-lm
sections of formaldehyde-fixed and paraffin-embedded
tissue. The tissues were deparaffinized with xylene and
rehydrated through graded concentrations of ethanol.
After rehydration, pretreatments with microwaves for
20 minutes for staining of CD45RO, CD45RA,
CD45LCA, Ki67; 0.05% protease XXIV at 37◦C for
20 minutes for staining of CD68; or proteinase K for
3 minutes at room temperature for staining of MAC387,
were performed. Primary antibodies included mouse
antihuman monoclonal antibodies directed against dif-
ferent subpopulations of macrophages (MAC387 and
CD68), lymphocytes (CD45RO for T cells and CD45RA
for B cells), and leukocyte common antigen (CD45LCA).
Ki67-clone MIP 1 was used for the detection of prolif-
erating cells. All antibodies were obtained from Dako
(Glastrup, Denmark). An alkaline phosphatase anti-
alkaline phosphatase (APAAP) (for MAC387, CD68,
CD45RO, CD45RA, CD45) or horseradish peroxidase
anti-peroxidase (PAP) (for Ki67) detection system was
applied for visualization. Controls, omitting the first anti-
body or replacing the first antibody by a nonimmune IgG
for each paraffin block tested, were negative. Immunohis-
tologically positive cells were counted in 20 HPF (HPF ×
40) of interstitium of cortex per section.
The numeric data generated by morphometry and
quantitative IHC were grouped by hierarchic clustering
as described for the gene expression data above.
Real-time RT-PCR
Two lg of total RNA was reverse transcribed in a
40-lL volume, containing 8 lL first-strand buffer (5×),
2 lL 100 mmol/L DTT (both Life technologies, Karlsruhe,
Germany), 0.8 lL 25 mmol/L dNTP (Amersham Pharma-
cia, Freiburg, Germany), 1 lL RNase inhibitor (RNasin,
Promega, Mannheim, Germany) and 0.5 lL Microcar-
rier (Molecular Research Center, Cincinnati, OH, USA),
0.86 lg random hexamers (2 mg/mL stock, Roche,
Mannheim, Germany), and 172 U reverse transcriptase
(Superscript I, Life technologies) for 1 hour at 42◦C.
Real-time reverse transcription-polymerase chain re-
action (RT-PCR) was performed on a TaqMan ABI
7700 Sequence Detection System (Applied Biosystems,
Weiterstadt, Germany) using heat-activated TaqDNA
polymerase (Amplitaq Gold, Applied Biosystems). Af-
ter an initial hold of 2 minutes at 50◦C and 10 minutes
at 95◦C the samples were cycled 40 times at 95◦C for
15 seconds and 60◦C for 60 seconds. For all quantitative
analyses cDNA content of each sample was compared
with another sample following the Ct technique or
standard curves, respectively [13–15]. Expression of 15 se-
lected transcripts was analyzed. For reconfirmation stud-
ies by real-time RT-PCR RNA 2 Con (Con 1, Con 3) and
7 HN samples (inflammatory HN: HN 1, HN 8; fibrotic
HN: HN 3, HN 4, HN 5, HN 6, and HN 9) were available.
Eighteen S rRNA and cyclophilin A were amplified in
parallel with the genes of interest. Quantification of gene
expression was performed using ABI 7700 Sequence De-
tection System software (Applied Biosystems). To ob-
tain the relative expression level of each gene of interest
ratios to 18S rRNA and cyclophilin A, as the two house-
keeping genes, were calculated. Sequences with Gene
Bank accession numbers listed in Table 1 served for the
design of the primer and probes or the selection of pre-
developed TaqMan assay reagents (PDAR). Primer and
probes for the genes of interest were designed in Primer-
Express (Applied Biosystems) and searched against the
public databases to confirm unique amplification prod-
ucts. Controls consisting of ddH2O were negative in all
runs. All measurements were performed in duplicates.
Ct values of duplicates were very similar (below 1.5 Ct)
or identical. The oligonucleotide primers (300 nmol/L)
and probes (100 nmol/L) employed are summarized in
Table 1.
Validation of candidate gene expression in renal biopsies
Human biopsies were obtained from patients after
informed consent and in compliance with permissions
obtained from the local ethical committees. A total of
32 renal biopsies available from the ERCB (European
Renal cDNA Bank, see appendix for participating cen-
ters) were evaluated. The samples represented a range
of histopathologic diagnoses. All biopsies were originally
stratified according to their histologic diagnosis by the
reference pathologist of the ERCB. Three biopsies with
no histologic lesions or minimal change glomerular dis-
ease (MCD) and no tubulointerstitial alterations visible
by histology, and four pretransplantation kidney biopsies
obtained during cold ischemia time from living donors
served as control (Con, N = 7) (Table 2). The degree of
tubulointerstitial damage was assessed by a semiquanti-
tative grading score. Severity of tubulointerstitial inflam-
mation or atrophy and fibrosis was rated as 0 = no injury,
1 = mild, 2 = moderate, and 3 = severe, respectively.
The 25 biopsies showing either prominent tubulointersti-
tial inflammation or fibrosis were used for validation and
characterization of candidate gene expression.
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Table 1. Primer and probes used for real-time RT-PCR
Gene Primer Accession No.
CXCR5 FP 5′-TTGCCTTGCCAGAGATTCTCTT-3′ NM 032966
RP 5′-TGAACCAGGCATGCGTTTC-3′
Probe FAM 5′-TGCCACGTTGCACCTTCTCCCAA-3′
Cyclophilin A PDAR Y00052
GPR5 FP 5′-CCTGGAGTCCCTCACCAACAT-3′ NM 005283
RP 5′-ATCCACACAGGCAACAAGCA-3′
Probe FAM 5′-TCATCCTCAACCTGTGCCTCTCAGACCT-3′
IL-8 PDAR Z11686
Integrin-b4 FP 5′-GCAAAAAGAGGTGCGGTCA-3′ NM 000213
RP 5′-CCACTCCAGCCCTCGCT-3′
Probe FAM 5′-CAACGGAGACTTCGTGTGCGGACA-3′
MCP-1 PDAR X14768
MIG FP 5′-TGCAAGGAACCCCAGTAGTGA-3′ NM 002416
RP 5′-GATTGTAGGTGGATAGTCCCTTGG-3′
Probe FAM 5′-TCGCTGTTCCTGCATCAGCACCA-3′
MIP-3b (ELC) FP 5′-AGAGGACCTCAGCCAAGATGAA-3′ AB000887
RP 5′-GACTCCGGGCTCCCTCTG-3′
Probe FAM 5′-CGCCGCAGCAGTTAACCTATGACCG-3′
MMP-3 FP 5′-GGAAGCTGGACTCCGACACTC-3′ NM 002422
RP 5′-TGGTGTATAATTCACAATCCTGTATGTAA-3′
Probe FAM 5′-CCTTTCCTGGCATCCCGAAGTGG-3′
MMP-7 FP 5′-TGGTAGCAGTCTAGGGATTAACTTCCT-3′ NM 002423
RP 5′-CATAGGTTGGATACATCACTGCATTA-3′
Probe FAM 5′-TGCTGCAACTCATGAACTTGGCCATT-3′
MMP-9 FP 5′-GAGGCGCTCATGTACCCTATGT-3′ NM 004994
RP 5′-CCGTGGCTCAGGTTCAGG-3′
Probe FAM 5′-ACGTGAATGGCATCCGGCACCTC-3′
SLC (6Ckine) FP 5′-CGCAGCTACCGGAAGCAG-3′ AB002409
RP 5′-CTGCCTGAGAGCGCTTGC-3′
Probe FAM 5′-CTCCATCCCAGCTATCCTGTTCTTGCC-3′
Pleiotrophin FP 5′-ATGCCGAATGCCAGAAGACT-3′ NM 002825
RP 5′-TTAGATTCTGCTTGAGGTTTGGG-3′
Probe 5′-CACCATCTCCAAGCCCTGTGGCAA-3′
rRNA 18S PDAR
TGF-b-R1 FP 5′-ACTGTAAAGTCATCACCTGGCCTT-3′ NM 004612
RP 5′-ACCATCAACATGAGTGAGATGCA-3′
Probe FAM 5′-AAGCACACTGGTCCAGCAATGACAGCT-3′
Urokinase R FP 5′-GCAACTCTGGCCGGGC-3′ NM 002659
RP 5′-AGCTCATGTCTGATGAGCCACA-3′
Probe FAM 5′-CCCGAAGCCGTTACCTCGAATGC-3′
VEGF FP 5′-GCCTTGCTGCTCTACCTCCAC-3′ NM 003376
RP 5′-ATGATTCTGCCCTCCTCCTTCT-3′
Probe FAM 5′-AAGTGGTCCCAGGCTGCACCCAT-3′
Abbreviations are: PCR, polymerase chain reaction; forward primer (FP); reverse primer (RP); fluorescence-labeled probe (probe FAM); predeveloped Taq Man
assay reagent (PDAR).
Sample preparation and processing was performed as
previously described [13]. In brief, tubulointerstitial tis-
sue was microdissected manually, RNA was isolated using
Qiagen RNeasy mini columns (Valencia, CA, USA), to-
tal RNA was reverse transcribed using random priming,
and real-time RT-PCR performed as described above.
Normalization of gene expression to levels of 18S
rRNA or cyclophilin A generally resulted in similar rela-
tive values when gene expression within tubulointerstitial
compartments of renal biopsies was studied. However,
when different interstitial renal disease states are studied
different normalization control genes can give slightly dif-
ferent values [16]. To address this, data derived using both
normalization genes are displayed in Figures 4 and 5. For
some mRNA markers, differential regulation is observed
only as ratio to a single housekeeper.
Correlation of gene expression data with clinical outcome
Clinical follow-up data for 10 of the patients collected
in a time period of 19.2 (±5.2) months from the date
of biopsy were available. Clinical parameters and corre-
sponding outcome are listed in Table 3.
Statistics
Statistical analysis was performed using the SPSS soft-
ware (version 10.0; SPSS, Inc., Chicago, IL, USA). Data
are given as mean ± standard error of the mean. Student
t test was used for paired data. Mean differences of non-
parametric data were analyzed by the Mann-Whitney U
test. The Kruskal-Wallis test was used to compare means
between more than two groups. Significance was assessed
using a Monte Carlo approach with a post-hoc Bonferroni
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Table 2. Clinical characteristics of renal biopsies analyzed by real-time RT-PCR in microdissected tubulointerstitium
Serum crea at ProtU at
Sample Age Sex biopsy mg/dL biopsy g/24h Inflammation Fibrosis Diagnosis
1 Con n.a. n.a. n.a. n.a. n.a. n.a. n.a.
2 Con n.a. n.a. n.a. n.a. n.a. n.a. n.a.
3 Con n.a. n.a. n.a. n.a. n.a. n.a. n.a.
4 Con n.a. n.a. n.a. n.a. n.a. n.a. n.a.
5 Con 32 m 1.3 11 0 0 MCD
6 Con 32 f 0.7 3 1 0 MCD
7 Con 20 f 0.5 6 0 0 MCD
8 Infl 23 m 3.58 4.2 2 0 IgA-nephropathy
9 Infl/Fibr 37 m 3.4 4.7 1 2.5 IgA-nephropathy + sec. FSGS
10 Infl/Fibr 47 m 7.6 n.a. 1 2.5 IgA-nephropathy + sec. FSGS
11 Fibr 72 m 3.3 6.3 0 3 IgA-nephropathy + sec. FSGS
12 Infl/Fibr 25 m 2 2.54 1 2.5 IgA-nephropathy + sec. FSGS
13 Fibr 51 m 2.9 2.1 0 2 IgA-nephropathy + sec. FSGS
14 Fibr 52 m 5.5 13 0 3 Membranous GN
15 Fibr 73 f 3.3 3.4 0 3 Membranous GN
16 Fibr 75 f 0.96 3 0 2 Membranous GN
17 Infl 47 m 1.12 10 3 0 Membranoprolif. GN
18 Infl 59 f 0.8 1.6 2 0 Membranoprolif. GN
19 Infl/Fibr 42 f n.a. n.a. 1 2.5 Lupus-nephritis (WHO IIIc)
20 Infl 73 m 2.9 3 1 0 PIRGN
21 Infl/Fibr 64 m 3.1 1.2 2 1 PIRGN
22 Infl 76 m 1.1 0.8 2 0 PIRGN
23 Infl 79 m 14 n.a. 1.5 0 PIRGN
24 Infl 19 m 2 n.a. 1 0 PIRGN
25 Infl/Fibr 66 m 3 2.1 3 1 PIRGN
26 Fibr 51 n.a. 8 n.a. 0 2.5 Benign nephrosclerosis
27 Infl/Fibr 66 m 9.86 1.72 1 2.5 Diabetic nephropathy
28 Fibr 77 m 2.86 3.1 0 3 Diabetic nephropathy
29 Infl 39 f 2.7 2.5 1.5 0 FSGS
30 Infl/Fibr 22 f 9 0.9 1.5 2 Chron. int. nephritis
31 Infl 65 m 3.7 n.a. 1.5 0 Mesangioprol. GN and int. nephritis
32 Fibr 25 m n.a. 6.8 0 2.5 Global glomerulosclerosis unclear etiology
Abbreviations are: MCD, minimal change disease; sec. FSGS, secondary focal segmental glomerulosclerosis; GN, glomerulonephritis; PIRGN, Pauci-immune rapid
progressive glomerulonephritis; Chron. int. nephritis, chronic interstitial nephritis. The samples have been graded with regards to inflammation (Infl) or fibrosis (Fibr)
or mixed morphology (Infl/Fibr) based on light microscopy performed by the ERCB reference Pathologist. For living donor biopsies clinical data were not available (n.a.).
Table 3. Clinical characteristics of the patients in Table 2 for whom follow-up data was available separated into those requiring renal replacement
therapy or stable renal function
Serum crea at ProtU at Follow-up ProtU at Serum crea at
Sample Age Sex biopsy mg/dL biopsy g/24h period months follow-up g/24h follow-up mg/dL Clinical course
Progression
13 Fibr 51 m 2.9 2.1 18 n.a. n.a. chron. hemodialysis
16 Fibr 75 f 0.96 3 27 n.a. n.a. chron. hemodialysis
27 Infl/Fibr 66 m 9.86 1.72 2 n.a. n.a. intermittent hemodialysis, death
30 Infl/Fibr 22 f 9 0.9 15 n.a. n.a. intermittent hemodialysis
32 Fibr 25 m 3.96 6.8 23 n.a. n.a. chron. hemodialysis
Chronic stable/remission
12 Infl/Fibr 25 m 2 2.54 20 0.6 1.6 chron. stable
19 Fibr 42 f 1.24 3 20 0.24 1.03 remission
20 Infl 73 m 2.9 3 19 1 3.11 chron. stable
28 Fibr 77 m 2.86 3.1 32 n.a. n.a. chron. stable
29 Infl 39 f 2.7 2.5 16 2.3 2.7 chron. stable
correction. P vales less than 0.05 were considered to be
statistically significant.
RESULTS
Characterization of disease
The DNA array study to identify molecular mark-
ers of renal tubulointerstitial disease was performed
using mRNA isolated from surgically removed human hy-
dronephrotic kidney tissues (HN, N =9) showing variable
degrees of inflammation, fibrosis, and tubular atrophy
and control kidneys (unaffected part of tumor nephrec-
tomies, Con, N = 3).
The diseased tissue was histologically characterized
with regards to inflammatory versus fibrotic disease
stages. The renal tissue was analyzed by a pathologist
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Fig. 1. Immunohistology of control (A, D) and hydronephrotic kidneys (B, E, C, F). Monocytes/macrophages were rarely demonstrated by CD68 in
control kidney (A). In peritubular capillaries and in hydronephrotic kidney with extensive fibrosis (C), but showed a strong signal in hydronephrotic
kidneys with an inflammatory infiltrate (B). Lymphocytes with the CD45RO antigen were seldom seen in control kidney (D), often documented in
hydronephrotic kidney with pronounced inflammatory infiltrate (E), and rarely seen in hydronephrotic kidney with extensive fibrosis (F). Alkaline
phosphatase antialkaline phosphatase (APAAP) reaction on formaldehyde-fixed paraffin-embedded tissue.
blinded with respect to the gene expression data us-
ing a set of morphometric and immunohistochemical
markers of proliferation, inflammation, fibrosis, and scar-
ring. Morphometric studies of features associated with
proliferation (Ki-67), infiltration by inflammatory cells
(leukocytes, T cells, B cells, monocytes/macrophages, and
granulocytes), and matrix alterations (Trichrome stain)
were performed. Two representative examples of domi-
nant inflammation (Fig. 1B and E) and fibrosis (Fig. 1C
and F) are provided. The relative values obtained for each
measurement from each sample (average number of pos-
itive cells obtained from 20 HPF) were then processed
using the cluster algorithm used for the gene expres-
sion data described below. The cluster dendrogram us-
ing the morphometric data separated the kidney samples
into three distinct groups: (1) Con group; (2) HN group
with high inflammation and low fibrosis (Inflam); and (3)
HN group with low inflammation and high fibrosis score
(Fibrosis) (Fig. 2).
Renal gene expression and disease processes
To identify differentially regulated mRNAs in tubu-
lointerstitial renal disease, gene expression analysis us-
ing custom DNA arrays was performed on total RNA
isolated from the control and HN kidneys. The custom
DNA array (see Methods) contained 375 genes repre-
senting gene products involved in cell-cell contact (inte-
grins), matrix turnover (proteases and their inhibitors),
cytokines, chemokines, and their receptors. A list of the
mRNAs that showed at least a 3.0-fold difference in ex-
pression relative to the average corresponding value in
the control tissues is given in Tables 4 and 5.
Molecular resolution of disease categories
To test if gene expression parameters allowed a
molecular-based disease categorization, gene expression
levels and samples were grouped with self organizing
maps and average linkage hierarchical clustering includ-
ing automatically weighted voting by applying programs
CLUSTER and TREEVIEW. The clustering algo-
rithm proceeds by first computing the distance between
all of genes in the dataset. When these distances are cal-
culated, the program joins the two items with the short-
est separation. These two genes are then removed from
the list and replaced by a branch. The distances between
this branch and all other genes are calculated once again
and the process repeated until all genes have been clus-
tered. The operator was blinded with respect to the his-
tologic disease categorization. After processing the data,
the dendrogram was visualized in TREEVIEW, where
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Fig. 2. Morphometric study, semiquantitative immunohistochemical
data defined the degree of tubulointerstitial inflammation, fibrosis, and
tubular atrophy. The quantitative analysis allowed the incorporation of
these data into a cluster dendrogram. The dendrogram of the x-axis
reflects the relationship among the samples by separating three groups
of samples: (I) Con, (II) HN group with high inflammation and low
fibrosis (Inflam), and (III) HN group with low inflammation and high
fibrosis score (Fibrosis). Con, control; HN, hydronephrosis; inflam, in-
flammation.
the tree structure reflects the relationship among the
samples.
Comparison of the sample classification using the gene
expression data to the IHC parameters revealed an iden-
tical separation pattern, indicating that sample segrega-
tion between chronic inflammation and fibrosis could be
performed by gene expression profiling. In brief, all clus-
ters obtained using the approach described above were
examined, and the aggregate change, or magnitude of
the expression change from normal, fibrosis, and inflam-
mation was determined across the cluster. Thus, a clus-
ter ranking system was produced where the total fold
changes of each gene in each sample member of the clus-
ter were summed. Discrimination between inflammation
and fibrosis could be seen in a subset of 31 genes extracted
from the clustered data. The set of genes were selected
based on: (1) Clear separation into histologic categories;
and (2) differential gene expression of at least 3-fold over
the control values (Fig. 3).
Confirmation of differential mRNA regulation
As DNA array data can show considerable variability,
the differential gene regulation was confirmed by an in-
dependent technique. A subgroup of 15 genes that were
representative markers of relevant subclusters (6Ckine,
IL-8, MMP-9, MMP-3, MMP-7, urokinase R, CXCR5,
integrin-b4, pleiotrophin, VEGF, MIG, GPR5, TGF-b
R1, MCP-1, and MIP-3b) was selected from the 31 genes
for further analysis. To confirm the reproducibility of the
mRNA expression levels the samples were evaluated by
real-time RT-PCR reactions using 18S rRNA and cy-
clophilin A for normalization. Real-time RT-PCR was
performed on 2 Con (Con 1, Con 3) and 7 HN sam-
ples (inflammatory HN: HN 1, HN 8; fibrotic HN: HN 3,
HN 4, HN 5, HN 6, and HN 9). A subgroup of 9 of these
genes (6Ckine, IL-8, MMP-7, MMP-3, MMP-9, urokinase
R, CXCR5, integrin-b4, pleiotrophin) allowed a stringent
differential expression between control and HN sam-
ples showing fibrosis versus inflammation. Figure 4 shows
the data describing the average mRNA expression levels
from the initial DNA array experiment and the subse-
quent RT-PCR ratios for the 9 genes relative to 18S rRNA
and cyclophilin A.
Evaluation of the identified marker set in routine
human renal biopsies
To validate the set of nine cDNAs as diagnostic marker
genes, their expression was determined in functioning
kidneys. Expression analysis was performed on 32 renal
biopsies representing seven control kidney tissue sam-
ples and 25 biopsies, reflecting a diverse set of renal
diseases taken from a routine diagnostic cDNA/biopsy
sample population. The individual samples were selected
according to their histologic features, showing prominent
tubulointerstitial inflammation or fibrosis based on eval-
uation by light microscopy performed by the reference
ERCB pathologist. Eight of the biopsies were classified
showing a high fibrosis score, nine with a high inflam-
mation score, and eight showing a mixed morphology
(Table 2).
Of the 9 genes studied (6Ckine, MMP-9, MMP-3,
MMP-7, urokinase R, CXCR5, integrin-b4, pleio-
trophin), differential mRNA expression between control
and diseased biopsy samples could be reliably obtained
for 6Ckine, MMP-9, MMP-3, MMP-7, and integrin-b4,
(Fig. 5). Differential expression between inflammatory
and fibrotic samples was seen with pleiotrophin and
urokinase R.
Correlation with clinical outcome and progression
of renal disease
To determine if gene expression profiles could provide
prognostic information, patient follow-up information
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Table 4. List representing genes associated with the inflammatory samples
Inflammation
Up Ratio Down Ratio
Gene Name Acc. No. Inflam/Con Gene Name Acc. No. Con/Inflam
CXCR-5 X68149 53,3 VEGF X62568 11,3
CXCR-2 M73969 52,0 Plasminogen M74220 9,5
SPC4 M80482 35,2 TNF-b D12614 6,2
Urokinase R Z46797 22,7 CD34 M81104 5,1
MMP-3 J03209 20,0 GAPDH M33197 4,9
MMP-7 NM 002423 11,3 N-Cadherin X54315 4,8
IL-8 Y00787 10,5 Angiopoietin-2 AF004327 4,7
TOSO AF057557 9,2 E-Cadherin Z13009 3,9
6Ckine AF001979 9,0 CAD-5 X79981 3,8
SLAM U33017 8,6 EMMPRIN X64364 3,8
CCR-6 Z79784 8,2 K-Cadherin D31784 3,6
GPR-5 L36149 6,9 BCAM X80026 3,5
FGF-7 M60828 6,8 BDNF X91251 3,5
Lymphotoxin b L11015 6,2 CD27L L08096 3,4
RANTES M21121 5,5 Integrin-a6 X53586 3,4
Ephrin-A3 U14187 5,1 IGF Binding Protein 4 M38177 3,1
FGF-17 AB009249 5,1 CKRL-2 AF027956 3,1
MIP-3a U77035 4,5 PECAM M28526 3,0
IL-7 Ra M29696 4,5
HCC-4 U91746 4,1
CD64 X14356 3,9
MMP-9 J05070 3,9
MCP-2 Y16645 3,8
PARC AB000221 3,8
Amphiregulin M30704 3,7
Integrin-b6 M35198 3,7
Ephrin-A5 U26403 3,7
Eotaxin D49372 3,6
IL-12 p35 M65271 3,6
TRAIL R3 AF012536 3,4
DNAM U56102 3,4
Pleiotrophin X52946 3,3
Lymphotactin U23772 3,3
CCR-7 L31581 3,3
GRO-a J03561 3,1
Genes were identified using the PanoramaTM Human Cytokine Gene Arrays that show at least a 3-fold dysregulation (either up or down) over the values seen in the
control tissue.
was correlated with the gene expression data. From the
25 disease biopsy samples, clinical follow-up data were
available for 10 of the patients. Follow-up data divided
the 10 patient samples into two groups showing different
clinical outcome: renal disease leading to hemodialysis
or to death was observed in five patients. The other five
patients showed either chronic stable renal function or re-
mission of disease (Table 2). Real-time RT-PCR expres-
sion data for the nine analyzed genes described above
were compared between both groups of patients. All an-
alyzed genes revealed a higher median expression level
in the group requiring renal replacement therapy.
Independent of the original characterization of the
biopsy samples, a subset of gene expression patterns was
able to distinguish between patients with stable disease
and those who progressed. A statistically significant dif-
ferential expression of IL-8, MMP-9, MMP-7, urokinase
R, and integrin-b4 was seen between the 2 patient groups
(Fig. 6A). Analysis of the expression and patient data us-
ing the cluster algorithm showed effective separation of
the patient groups according to clinical outcome (Fig. 6B).
DISCUSSION
The diagnosis of renal disease is commonly based
on histomorphologic evaluation including ultrastructural
features and analysis of limited immunohistochemical
markers. The study performed here describes a compar-
ison of conventional histopathologic classification with
gene expression profiling, and was proposed to verify the
hypothesis that differentially regulated genes could be
used to reiterate the segregation of different disease pro-
cesses using standard histopathologic procedures. In ad-
dition, we tested if molecular parameters could also act
as potential disease predictors.
Combining DNA microarray techniques and clustering
approaches has proven successful for the classification
and molecular profiling of cancerous tissue [1, 10, 17–
19], but has not yet been generally applied to complex
heterogeneous tissues like the kidney.
As an initial step, an exemplary renal disease state
was required that would readily allow gene expression
analysis and pathologic characterization. To this end, hy-
dronephrosis (HN) samples were used. HN was selected
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Table 5. List of genes differentially regulated in the HN samples scored as fibrotic
Fibrosis
Up Ratio Down Ratio
Gene Name Acc. No. Fibrosis/Con Gene Name Acc. No. Con/Fibrosis
CNTF Ra M73238 61,4 IGF-I R X04434 32,0
MMP-13 X75308 19,5 TGF-b RI AF054598 21,0
CXCR-5 X68149 16,6 IL-3 Ra M74782 18,2
MIP-3b AB000887 13,9 CD27L L08096 17,9
HCC-1 Z70292 13,7 GPR-5 L36149 12,7
MMP-14 D26512 13,6 Osteoprotegerin U94332 11,1
Urokinase R Z46797 12,0 BCAM X80026 10,1
Pleiotrophin X52946 11,6 ALCAM L38608 9,4
MMP-3 J03209 10,3 SARP-3 AF017988 8,4
Integrin-b4 X51841 8,0 Bob U34806 8,3
Follistatin M19480 6,6 BMP-6 NM 001718 7,7
FGF-13 U66198 6,2 Leptin U18915 6,5
SPC4 M80482 6,2 Integrin-a9 L24158 6,1
TOSO AF057557 6,0 MIG X72755 6,0
NGF R M14764 6,0 B7-2 L25259 6,0
SLAM U33017 5,8 N-Cadherin X54315 5,6
GFRa1 U97144 5,6 ICAM-3 S50015 5,2
6Ckine AF001979 5,4 MPL R M90102 5,0
Lymphotactin U23772 5,4 EphA1 M18391 4,5
TIMP-2 M32304 5,2 B7-1 M27533 4,5
GRO-b M36820 5,0 gp130 M57230 4,0
HB-EGF M60278 4,9 R-Cadherin L34059 3,7
CXCR-2 M73969 4,7 Osteopontin J04765 3,6
erbB4 L07868 4,6 EphB3 X75208 3,5
BMP-3 M22491 4,5 HGF M29145 3,4
IL-9 Ra M84747 4,5 K-Cadherin D31784 3,4
IGF-I X56773 4,1 VEGF-B U43368 3,4
MCP-2 Y16645 4,1 BMP RIB U89326 3,3
CD21 M26004 3,8 IGF Binding Protein 4 M38177 3,1
Activin RIIA M93415 3,8 GM-CSF Ra X17648 3,0
Eotaxin D49372 3,7 GAPDH M33197 3,0
IL-8 Y00787 3,7 Tie-2 L06139 3,0
AXL M76125 3,7
Midkine M69148 3,6
TNF RII M55994 3,6
TRAIL R1 U90875 3,5
GRO-a J03561 3,2
FGF-7 M60828 3,1
IL-6 M14584 3,1
SARP-1 AF017986 3,1
MCP-1 S69738 3,0
MCP-3 X71087 3,0
NT-3 M37763 3,0
HN is hydronephrosis. Genes were identified using the PanoramaTM Human Cytokine Gene Arrays that show at least a 3-fold dysregulation (either up or down) over
the values seen in the control tissue.
for three reasons: first, the underlying disease was not
a continuum of disease stages but a clinical end point;
second, entities of inflammation versus tubulointerstitial
fibrosis could be reliably and easily determined in rela-
tively large tissue areas using conventional histopatho-
logic approaches; and third, adequate tissue samples for
the DNA array as well as the real-time RT-PCR studies
were available in the majority of cases.
The disease alterations in HN consist of a variable de-
gree of infiltrating inflammatory cells and a progressive
interstitial scarring process with diffuse areas of tissue
remodeling and fibrosis [1, 17].
It is assumed that the cellular composition of the le-
sions would have a major impact on gene expression
patterns. During renal disease, the infiltration of mono-
cytes/macrophages and T cells into kidneys is thought to
play a central role in progressive interstitial fibrosis and
the progression of renal failure [20]. The disease process
in each HN and control kidney was analyzed for subpop-
ulations of infiltrating mononuclear cells, proliferation
markers, and scarring. Processing of the morphometric
data using the Eisen clustering algorithm showed a clear
separation into three groups: (1) the Con group; (2) HN
group with high inflammation and low fibrosis (Inflam);
and (3) HN group with low inflammation and high fibrosis
scores (Fibrosis) indicating a robust classification.
Gene expression profiling can rapidly analyze hun-
dreds or thousands of genes in parallel and has been
Henger and Kretzler et al: Gene expression in inflammation and fibrosis 913
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Fig. 3. Cluster analysis of 375 genes. Cluster
analysis was performed on log-transformed
values of the fold ratios with gene CLUS-
TER and visualized in TREEVIEW. The sam-
ples are represented in the columns and the
genes in the rows. The name of each gene is
shown at the right side of each row. Genes that
were present at higher levels in the examined
group (increased) are shown in progressively
brighter shades of red, depending on the fold
difference, and genes that were expressed at
lower levels (decreased) are shown in progres-
sively brighter shades of green. Genes shown
in black were not different between the groups
being compared. Genes shown in gray were
not expressed. The cluster dendrogram of the
y-axis shows predictive genes extracted from
the whole gene set. Genes are grouped ac-
cording the similarity of their expression pro-
file. The degree of similarity and relationship
among genes (and samples) are represented
by the length of the branches (the shorter, the
higher the similarity). The color-coded matrix
and the dendrogram of the x-axis reflects the
relationship among the samples by separat-
ing the identical three groups as known from
clustering immunohistologic data. Grouping
of genes with similar expression is reflected
by the tree on the left side. A cluster con-
taining 31 genes showing at least 3-fold
difference in expression relative to control
samples was determined to provide the great-
est expression level of separation of control,
hydronephrosis with dominant inflammation,
and hydronephrosis with dominant fibrosis.
shown to establish a disease-specific profile of regulated
genes [8]. For the DNA array analysis, a custom cDNA
filter array containing 375 cDNAs generating an expres-
sion profile of chemokines, cytokines, their receptors, in-
tegrins, and matrix modulating molecules was used. This
DNA array was selected because it contained a specific
series of genes known to play diverse roles in fibrosis and
inflammation (PanoramaTM Human Cytokine Gene Ar-
rays; Sigma Genosys, Inc.).
Hierarchical clustering of the whole expression data
set resulted in clear separation into three kidney groups:
one control group and two distinct HN groups, thus es-
tablishing complete concordance between the conven-
tional microscopic and the gene expression classification.
A subgroup of nine genes that were strongly differen-
tially regulated between the two hydronephrosis groups
was eventually selected for further study. 6Ckine, IL-8,
MMP-9, MMP-3, MMP-7, urokinase R, CXCR5 mRNA
were induced in the inflammation group, integrin-b4 and
pleiotrophin mRNA in the fibrotic group.
HN as studied here represents an extreme example of
gene expression features at an end-stage disease process.
It is not expected that all of the genes found differen-
tially expressed in this model system would necessarily
be differentially expressed in other chronic renal disease
processes. However, it is reasonable to expect that a sub-
group of the differentially expressed genes identified in
different examples of HN could identify similar processes
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in samples of other kidney diseases. The validation of this
hypothesis was tested in a set of renal biopsies.
Biopsy samples were selected for their general fibrosis
versus inflammatory characteristics (Table 2). This was
based on a qualitative separation of biopsies by light
microscopy performed by reference ERCB pathologists.
The samples could be differentiated into subgroups, to
a significant degree, based on gene expression profiles.
It is important to consider that these biopsy samples
do not represent end points of a disease process. They
mirror a process, in progression or remission, with a
varying overlap of smoldering chronic inflammation and
reversible or fixed irreversible fibrosis. In addition, they
had not been characterized as extensively as the HN
samples used for the initial analysis. For example, analy-
sis of immunocompetent cells, of proliferation, or extent
of fibrosis was not performed. That said, the expression
profiles did show a trend toward differential expression
across the samples tested. Other genes (i.e., CXCR-5) did
not show the same degree of differential regulation in the
biopsy samples as seen in the end-stage hydronephrotic
kidneys, most likely reflecting the mild-to-severe renal in-
sufficiency represented by the biopsy samples examined.
Interestingly, a more striking correlation was seen when
expression of all the identified genes relative to patient
follow-up data were analyzed.
We asked if gene expression profiles could also pro-
vide some level of prognostic information. To this end,
10 patient samples, where follow-up data was available,
were divided into two groups reflecting differential clini-
cal outcome: disease course requiring renal replacement
therapy, or chronic stable renal function/remission. The
set of genes showing predictive ability for poor renal
outcome was independent of the original morphologic
characterization of biopsy samples and involved genes
previously identified as inflammatory or fibrotic. IL-8,
MMP-9, MMP-7, urokinase R, and integrin-b4 showed
statistically significant differences between both patient
groups and suggest pathophysiologic changes that may
be important in progression of renal disease. The cluster
algorithm employed allowed segregation of the patient
samples into good or poor renal outcome, based solely
on the gene expression data.
Despite advances in understanding of progressive re-
nal diseases, its complex regulatory pathways remain to
be elucidated. Here, a set of genes known to be involved
in diverse aspects of inflammatory processes and tissue
remodeling were found differentially expressed in pro-
gressive renal dysfunction. Chemokines and their recep-
tors were found differentially expressed. Chemokines
help control leukocyte influx into tissue [21]. IL-8/CXCL8
induction, for example, is observed in human renal allo-
grafts undergoing rejection and in a variety of glomeru-
lonephritidies [22, 23]. Matrix metalloproteinases such
as MMP-3, MMP-9, and MMP-7 are involved in a variety
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Fig. 5. Real time RT-PCR quantification of mRNA expression of the nine candidate genes in a series of renal biopsies grouped by characterization
of level of inflammation (I) versus fibrosis (F) or mixed morphology (I/F). The graphs show expression ratios of each gene to 18S rRNA (A) and
cyclophilin A (B) in the renal biopsies. RT-PCR, reverse transcription-polymerase chain reaction.
of pathophysiologic processes, including invasive cell be-
havior, inflammation, tissue remodeling, and repair [24].
Urokinase receptor functions as a proteinase receptor
and affects migration, adhesion, differentiation, and pro-
liferation by the initiation of complex intracellular signal
transduction pathways [25]. Pleiotrophin is a ligand of the
receptor ALK (anaplastic lymphoma kinase), which can
act as an oncogene and induce transformation in fibrob-
lasts [26]. Integrins are involved in the regulation of cell
survival, migration, and differentiation, as well as bidi-
rectional signal transduction across the cell membrane
[27, 28].
The diagnostic and prognostic information associated
with the expression of these genes may support the poten-
tial roles of their gene products in the associated disease
processes. In addition, the identification of differentially
expressed genes associated with a defined subset of dis-
eased kidneys may also prove useful in the development
of novel therapeutic strategies.
The identification of molecular markers that show dif-
ferential expression levels between inflammation and fi-
brosis in hydronephrotic kidneys suggests the feasibility
of molecular categorization of renal disease. Because re-
nal inflammation, as compared with progressive fibrosis,
can be therapeutically altered, a set of additional markers
may be particularly useful in this setting.
The relatively small-scale study described here pro-
vides proof of principle that it is possible to characterize
pathologic features of renal biopsy samples based on the
expression patterns of a limited number of genes. More
importantly, a subgroup of genes can also provide prog-
nostic information about the progression of disease. Be-
cause, to date, this is beyond conventional renal biopsy
analysis, molecular analysis offers the chance to yield
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fundamentally novel kind of information concerning dis-
ease prognosis, a crucial aspect of patient care.
The diagnostic value of identified markers for poor
clinical outcome has to be examined in a prospective
study beyond disease classification. This could be a cru-
cial next step for obtaining prognostic information out of
mRNA expression data in addition to pathologic disease
classification.
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